Cue Biopharma Inc.
Organization details
- Legal name
- Cue Biopharma Inc.
- Former names
- Imagen Biopharma, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CUE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001645460
- EIN
- 47-3324577
Board of directors
-
Aaron G.l. Fletcher · DirectorSince 2023
-
Daniel A. Camardo · DirectorSince 2026
-
Daniel R. Passeri · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Frank Morich · DirectorSince 2023
-
Frederick W. Driscoll · DirectorSince 2023
-
Jill Marie Broadfoot · DirectorSince 2025
-
Michael J. Fox · DirectorSince 2024
-
Pamela Garzone · DirectorSince 2023
-
Pasha Sarraf · DirectorSince 2025
-
Patrick Verheyen · DirectorSince 2023
-
Peter A. Kiener · DirectorSince 2023
-
Shao-Lee Lin · Director · Chief Executive OfficerSince 2026
-
Tamar D. Howson · DirectorSince 2023
-
Usman Azam · Director · CHIEF EXECUTIVE OFFICERSince 2025
-
Viola Mong Meehan · DirectorSince 2026
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
195.8% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of April 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
61.8%
-
62.7%
-
69.0%
-
69.7%
-
89.3%
-
90.6%
Board connections
7 of this board's directors also sit on 9 other boards. 9 are in the same sector.
-
Lite Strategy Inc. Same sectorvia Frederick W. Driscoll and Tamar D. Howson
-
Actuate Therapeutics Inc. Same sectorvia Aaron G.l. Fletcher
-
Cellectar Biosciences Inc. Same sectorvia Frederick W. Driscoll
-
Cognition Therapeutics Inc. Same sectorvia Aaron G.l. Fletcher
-
Immunic Inc. Same sectorvia Tamar D. Howson
-
Palvella Therapeutics Inc. Same sectorvia Peter A. Kiener
-
Perspective Therapeutics Inc. Same sectorvia Frank Morich
-
Surrozen Inc. Same sectorvia Shao-Lee Lin
-
Talphera Inc. Same sectorvia Jill Marie Broadfoot
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $99,719
- 5 purchases by 1 insider
- Sold, last 12 months
- $2,041,514
- 11 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Option exercise | +18,196 | — | — |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Option exercise | +13,647 | — | — |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −2,383 | $29.37 | $69,989 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −1,519 | $29.37 | $44,613 |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −6,442 | $30.35 | $195,515 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −4,106 | $30.35 | $124,617 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −5,423 | $27.19 | $147,451 |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −4 | $31.13 | $125 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −3 | $31.13 | $93 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,375 | $28.11 | $66,761 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −10,460 | $29.48 | $308,361 |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Option exercise | +109,179 | — | — |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −34,225 | $26.99 | $923,733 |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −5,775 | $27.75 | $160,256 |
| Jul 30, 2026 | Ahlers James M Officer (Chief Financial Officer) | Grant or award | +25,500 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Cue Biopharma Inc.
Who is the CEO of Cue Biopharma Inc.?
Shao-Lee Lin has been Cue Biopharma Inc.'s Chief Executive Officer since April 2026.
How many directors are on Cue Biopharma Inc.'s board?
Cue Biopharma Inc.'s board has 15 directors: Aaron G.l. Fletcher, Daniel A. Camardo, Daniel R. Passeri, Frank Morich, Frederick W. Driscoll, Jill Marie Broadfoot, Michael J. Fox, Pamela Garzone, Pasha Sarraf, Patrick Verheyen and 5 others.
Are Cue Biopharma Inc. insiders buying or selling shares?
Over the last 12 months, Cue Biopharma Inc. insiders bought $99,719 of shares in 5 purchases and sold $2.0 million of shares in 11 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cue-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.